Poolbeg Pharma Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Jeremy Skillington
Chief executive officer
UK£362.0k
Total compensation
| CEO salary percentage | 69.1% |
| CEO tenure | 3.5yrs |
| CEO ownership | 0.2% |
| Management average tenure | 1yrs |
| Board average tenure | 3.5yrs |
Recent management updates
Recent updates
Companies Like Poolbeg Pharma (LON:POLB) Are In A Position To Invest In Growth
Aug 20
We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely
Feb 16We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely
Oct 05We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely
Jun 01Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation
Jul 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -UK£4m |
| Mar 31 2024 | n/a | n/a | -UK£4m |
| Dec 31 2023 | UK£362k | UK£250k | -UK£4m |
| Sep 30 2023 | n/a | n/a | -UK£4m |
| Jun 30 2023 | n/a | n/a | -UK£5m |
| Mar 31 2023 | n/a | n/a | -UK£5m |
| Dec 31 2022 | UK£310k | UK£250k | -UK£5m |
| Dec 31 2021 | UK£261k | n/a | -UK£3m |
Compensation vs Market: Jeremy's total compensation ($USD454.07K) is above average for companies of similar size in the UK market ($USD346.72K).
Compensation vs Earnings: Jeremy's compensation has increased whilst the company is unprofitable.
CEO
Jeremy Skillington (53 yo)
3.5yrs
Tenure
UK£362,000
Compensation
Dr. Jeremy Skillington, Ph D., serves as Chief Executive Officer and since July 19, 2021 as Director at Poolbeg Pharma PLC. He is Vice President of Business Development at Inflazome Ltd.Dr. Skillington se...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of The Board | 3.8yrs | UK£150.00k | 4.36% £ 915.4k | |
| CEO & Director | no data | UK£362.00k | 0.17% £ 36.7k | |
| CFO & Director | no data | UK£237.00k | 1.67% £ 349.7k | |
| Vice President of Investor Relations & Public Relations | 1.9yrs | no data | no data | |
| Senior Vice President & Chief Legal Officer | less than a year | no data | no data | |
| Chief Business Officer | 1.1yrs | no data | no data | |
| Group Financial Controller | no data | no data | no data |
1.0yrs
Average Tenure
53.5yo
Average Age
Experienced Management: POLB's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of The Board | 3.8yrs | UK£150.00k | 4.36% £ 915.4k | |
| CEO & Director | 3.5yrs | UK£362.00k | 0.17% £ 36.7k | |
| CFO & Director | 3.7yrs | UK£237.00k | 1.67% £ 349.7k | |
| Independent Non-Executive Director & Member of Scientific Advisory Board | 3.5yrs | UK£40.00k | no data | |
| Member of Scientific Advisory Board & Independent Non Executive Director | 2.1yrs | UK£24.00k | 0.53% £ 110.5k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Senior Independent Director | 3.5yrs | UK£35.00k | no data | |
| Member of Scientific Advisory Board | 3.2yrs | no data | no data |
3.5yrs
Average Tenure
60yo
Average Age
Experienced Board: POLB's board of directors are considered experienced (3.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 21:12 |
| End of Day Share Price | 2025/01/06 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Poolbeg Pharma PLC is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Adam McCarter | Cavendish |
| Brian White | Shore Capital Group Ltd |